Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Art Krieg, Philip Ranker, Richard Ho

Premium

Art Krieg has been named as CSO of RNA drug developer Sarepta Therapeutics.

Krieg previously served as CEO of gene-activation firm Rana Therapeutics, which he cofounded in 2011. Before that, he led Pfizer's oligonucleotide therapeutics unit.

He remains a Rana senior advisor and scientific advisory board member.


Troubled RNAi drug firm Marina Biotech disclosed this month the resignations of CFO Philip Ranker and executive VP of research and development Richard Ho.

The departures come after Marina shut down essentially all of its operations in mid-2012 due to lack of funding.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.